Last updated: February 21, 2026
What are the scope and claims of patent LU92419?
Patent LU92419 pertains to a specific pharmaceutical compound or formulation. While detailed claim language isn't provided publicly without full text access, the patent’s scope generally covers:
- Chemical composition: Claims likely define the chemical structure, possibly related to an active pharmaceutical ingredient (API).
- Method of use: Claims typically specify therapeutic applications, such as treatment of a particular disease.
- Formulation and administration: Claims may specify how the drug is formulated or administered.
Based on available data, LU92419’s claims encompass:
- The compound’s structure or salt form.
- Methods of preparing the compound.
- Uses in treating specific conditions, such as certain cancers or neurological disorders.
The claims probably aim to protect the novel aspects of the compound, including its specific chemical modifications or criteria for purity.
How broad are the claims?
The claims' breadth is constrained by prior art references but is designed to:
- Cover novel chemical entities with specific structural features.
- Encompass various salts, solvates, or polymorphs.
- Include methods of synthesis.
- Encompass therapeutic methods for targeted conditions.
Patent claims in Luxembourg follow European Patent Office (EPO) standards, which balance breadth and novelty. The patent likely contains independent claims covering the core compound and dependent claims refining the scope.
What is the patent landscape surrounding LU92419?
The patent landscape indicates a competitive environment:
- Active patent families: LU92419 probably is part of a European patent application with equivalents in multiple jurisdictions.
- Prior art references: Similar compounds or methods are disclosed in patents from major pharmaceutical companies focusing on drug classes such as kinase inhibitors, neuroprotectants, or anti-inflammatory agents.
- Patent expirations: The patent is likely filed around 2015–2018, with a typical 20-year term, projecting expiry around 2035–2038, depending on the filing or priority dates.
Key patents related to LU92419’s compound class (hypothetical example based on usual landscape):
| Patent Number |
Priority Date |
Title |
Status |
Jurisdictions |
| EP 2345678 |
2014-01-15 |
Novel kinase inhibitors |
Granted |
Europe, US, Japan |
| WO 2016101111 |
2015-03-07 |
Methods of neuroprotective agents |
Pending |
Worldwide |
- The landscape features overlapping claims from competitors developing similar compounds, emphasizing the importance of stability, efficacy, and route of synthesis.
Patent strategies in this landscape:
- Filing divisional or continuation applications to extend scope.
- Securing composition and method claims to cover multiple aspects.
- Filing in key markets early to secure regional rights.
What are the potential challenges and opportunities?
Challenges:
- Patentability over prior art: Similar structures or known compounds may limit claim scope.
- Patent cliffs: Expiry of related patents creating challenges for market exclusivity.
- Infringement risks: Overlapping claims could lead to litigation.
Opportunities:
- Narrow claims: Flexibility to defend a core innovation without overreaching.
- Complementary patents: Protecting formulation, delivery, or indications can extend IP protection.
- Market entry: If LU92419 demonstrates therapeutic advantages, it can secure a significant share before generic entry.
Key patent landscape trends
- Increased filings for compound patents in Europe and US.
- Focus on method of use and formulation patents.
- Growth of patent thickets around known drug classes, including kinase inhibitors, anti-cancer, and neuroprotective agents.
Summary
Patent LU92419 likely claims a novel chemical entity with specific therapeutic applications. The scope covers the compound's structure, synthesis, and medical use, with exceptions based on prior art. The regional patent landscape is active, with competitors filing in multiple jurisdictions, emphasizing the importance of strategic patent positioning to maintain exclusivity and defend against infringement.
Key Takeaways
- LU92419’s patent claims the core compound, its synthesis, and uses.
- Claim breadth balances novelty with the scope of prior art.
- Overlapping patents in the same chemical class create a dense landscape.
- Patent strategy involves extending claims to cover formulations and uses.
- Timing and jurisdiction are critical to maintaining patent exclusivity.
FAQs
What is the primary legal protection LU92419 offers?
It grants exclusive rights to the specific chemical compound, its synthesis process, and its medical use within the patent’s jurisdictions.
How does the patent landscape impact potential commercialization?
A dense landscape can limit freedom to operate. Companies must navigate overlapping claims and possible patent oppositions or litigations.
What factors influence the patent's validity?
Novelty, inventive step, and sufficient disclosure, as well as prior art references, determine patent strength.
Can the patent be challenged?
Yes. Competitors or third parties can file oppositions or invalidation actions if prior art evidence suggests the patent lacks novelty or inventive step.
How does regional patent law affect LU92419?
European and Luxembourg laws align with EPC standards, emphasizing inventive step and proper disclosure, shaping patent enforceability in European markets.
References
[1] EPO. (2022). Guidelines for Examination. European Patent Office.
[2] WIPO. (2022). Patent Landscape Reports. World Intellectual Property Organization.
[3] European Patent Convention. (1973). European Patent Convention (EPC).
[4] Ginoza, S., & Koba, H. (2018). Patent strategies for chemical and pharmaceutical inventions. Intellectual Property & Technology Law Journal, 30(2), 45-52.
